BCL-XL inhibitor

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

May, 2025

BCL-XL inhibitor

Jan 18, 2024, 11:27 | Insight

Hagop Kantarjian: Hyper-CVD + venetoclax achieves CR/CRi rate of 57% in heavily treated relapsed/refractory Acute Lymphoblastic Leukemia

Hagop Kantarjian, Chair of the Department of Leukemia at The University of Texas MD Anderson…

All: 1 Posts: 1 - 100

'

Oncologist Near Me – Yan Leyfman: A Voice for Innovation, Mentorship, and Impact in Oncology

'

Richard Goldberg: Agenus Anticipates Interacting with FDA with New Data Coming at ESMO-GI 2025

'

USA vs Europe: Who Does Cancer Screening Better?

'

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

'

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023